Market Cap 52.30M
Revenue (ttm) 0.00
Net Income (ttm) -25.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 541,900
Avg Vol 270,706
Day's Range N/A - N/A
Shares Out 19.81M
Stochastic %K 57%
Beta 1.59
Analysts Strong Sell
Price Target $33.67

Company Profile

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-f...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 254 6134
Address:
1201 Orange Street, Suite 600, Wilmington, United States
the_franz
the_franz Aug. 26 at 7:18 AM
$NRXP I am aware that after @larumba's departure I am the only one here interested in the chronic pain topic. I occasionally check in to Northwestern's clinical trials page. They still try to submit their results correctly. 🤣 Now they seem to differ between safety popuplation and efficacy one as there has been an error on dispensing the drug. These amateurs botched their DoD-financed trial or how should I read that? "There was an error in the study drug dispensation process that resulted in the incorrect treatment assignment being dispensed. Adverse events are reported for all participants who were randomized (n=203) based on the treatment received (safety population). For the primary efficacy outcome results, only those participants who were enrolled up to the time of the error in allocation were included in those analyses (n=170)."
0 · Reply
benzinga
benzinga Aug. 25 at 9:31 PM
NRx Pharmaceuticals' Approach To Treating Depression And Suicide Ideation Brings Modern Solution To Centuries-Old Problem $NRXP https://www.benzinga.com/partner/biotech/25/08/47316557/nrx-pharmaceuticals-approach-to-treating-depression-and-suicide-ideation-brings-modern-solution-t
0 · Reply
RichTheKing
RichTheKing Aug. 25 at 9:04 PM
$NRXP nice vol today
1 · Reply
Lloydclat
Lloydclat Aug. 25 at 5:58 PM
1 · Reply
Lloydclat
Lloydclat Aug. 25 at 5:57 PM
1 · Reply
jonny80s
jonny80s Aug. 25 at 5:11 PM
$NRXP instead of warrants with share offerings now Javitt can offer baggets. One bagget per 10 share block.
1 · Reply
jsnethen
jsnethen Aug. 25 at 4:39 PM
$NRXP https://psychedelicalpha.com/news/norway-approves-public-funding-for-generic-ketamine-in-treatment-resistant-depression
1 · Reply
John_D_Stockefeller
John_D_Stockefeller Aug. 25 at 4:00 PM
$NRXP Sux when Dr. Jammit’s turd of a stock is your biggest % gainer on the day. Back to bed…….zzzzzz
1 · Reply
BlazingStocks
BlazingStocks Aug. 25 at 2:05 PM
$NRXP News August 12, 2025 NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025 https://finance.yahoo.com/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-200500543.html
0 · Reply
WhereDidAllTheMoneyGo
WhereDidAllTheMoneyGo Aug. 25 at 2:05 PM
$NRXP Trading is back in Europe at Tradegate stock exchange, i.e. ING Bank via Direkthandel! Very positive development!
0 · Reply
Latest News on NRXP
NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 10:50 AM EDT - 5 months ago

NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript


NRx Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript

Nov 18, 2024, 7:51 PM EST - 10 months ago

NRx Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript


the_franz
the_franz Aug. 26 at 7:18 AM
$NRXP I am aware that after @larumba's departure I am the only one here interested in the chronic pain topic. I occasionally check in to Northwestern's clinical trials page. They still try to submit their results correctly. 🤣 Now they seem to differ between safety popuplation and efficacy one as there has been an error on dispensing the drug. These amateurs botched their DoD-financed trial or how should I read that? "There was an error in the study drug dispensation process that resulted in the incorrect treatment assignment being dispensed. Adverse events are reported for all participants who were randomized (n=203) based on the treatment received (safety population). For the primary efficacy outcome results, only those participants who were enrolled up to the time of the error in allocation were included in those analyses (n=170)."
0 · Reply
benzinga
benzinga Aug. 25 at 9:31 PM
NRx Pharmaceuticals' Approach To Treating Depression And Suicide Ideation Brings Modern Solution To Centuries-Old Problem $NRXP https://www.benzinga.com/partner/biotech/25/08/47316557/nrx-pharmaceuticals-approach-to-treating-depression-and-suicide-ideation-brings-modern-solution-t
0 · Reply
RichTheKing
RichTheKing Aug. 25 at 9:04 PM
$NRXP nice vol today
1 · Reply
Lloydclat
Lloydclat Aug. 25 at 5:58 PM
1 · Reply
Lloydclat
Lloydclat Aug. 25 at 5:57 PM
1 · Reply
jonny80s
jonny80s Aug. 25 at 5:11 PM
$NRXP instead of warrants with share offerings now Javitt can offer baggets. One bagget per 10 share block.
1 · Reply
jsnethen
jsnethen Aug. 25 at 4:39 PM
$NRXP https://psychedelicalpha.com/news/norway-approves-public-funding-for-generic-ketamine-in-treatment-resistant-depression
1 · Reply
John_D_Stockefeller
John_D_Stockefeller Aug. 25 at 4:00 PM
$NRXP Sux when Dr. Jammit’s turd of a stock is your biggest % gainer on the day. Back to bed…….zzzzzz
1 · Reply
BlazingStocks
BlazingStocks Aug. 25 at 2:05 PM
$NRXP News August 12, 2025 NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025 https://finance.yahoo.com/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-200500543.html
0 · Reply
WhereDidAllTheMoneyGo
WhereDidAllTheMoneyGo Aug. 25 at 2:05 PM
$NRXP Trading is back in Europe at Tradegate stock exchange, i.e. ING Bank via Direkthandel! Very positive development!
0 · Reply
the_franz
the_franz Aug. 25 at 1:45 PM
$NRXP Oh boy, seriously. You simply cannot make this shit up! According to Shrader, HOPE will generate revenues in Q3 of $13.5m. In Q4 $16.5m. So Q3, which ends in 5 weeks, has only $3M revenues less than 3 whole fucking months of Q4! Let's continue. In 2025 his HOPE revenue estimates equate to $30M. In 2026 HOPE will earn us $41.7m. So Schrader sees a declining business here. Maybe we should leave it at all with the clinics. 🤣 Let's continue, and this could be important for the cheerleaders here. He estimates the potential of NRX-100 with revenues in 2026(!) of $858K. There isn't a single reasonable analyst covering this stock! Not one who gives you the impression that he is really engaged with the company, has read up on it, and understands where its potential lies. Just people playing their own games to get these commissions. Screw them all.
1 · Reply
the_franz
the_franz Aug. 25 at 1:25 PM
$NRXP BTIG's Shrader: "ANDA submission is complete". Well, someone did not look into EDGAR... Who's going to tell him? 🤣
0 · Reply
stockinfocuz_
stockinfocuz_ Aug. 25 at 1:17 PM
NRX Pharmaceuticals Inc (NRXP, Buy, $25 PT) $NRXP https://www.nrxpharma.com/wp-content/uploads/2025/08/2Q25-Update.-Progress-on-Most-Fronts.-FDA-Acceptance-for-the.pdf
1 · Reply
stockinfocuz_
stockinfocuz_ Aug. 25 at 1:09 PM
$NRXP New analyst report from BTIG - NRX Pharmaceuticals Inc (NRXP, Buy, $25 PT): 2Q25 Update. Progress on Most Fronts. FDA Acceptance for the NDA Detailing Read Report - https://nrxpharma.com/wp-content/uploads/2025/08/2Q25-Update.-Progress-on-Most-Fronts.-FDA-Acceptance-for-the.pdf
0 · Reply
Siddy_Sauce
Siddy_Sauce Aug. 25 at 12:51 PM
$NRXP why is that an issue ? Lol
5 · Reply
jonny80s
jonny80s Aug. 25 at 12:48 PM
$NRXP someone enter Javitt in the Guinness Book of World Records: first pre-revenue biotech CEO to open a restaurant while attempting to get his first drug approved by the FDA. You can’t make this shit up….. @JavittMD
0 · Reply
Siddy_Sauce
Siddy_Sauce Aug. 25 at 12:42 PM
$NRXP this is sooooo gonna pop soon!! People question the £34 target price, I don’t I think it will be increased again shortly, we have so many catalyst about to land its crazy not to be in this! Load the boat!!
1 · Reply
Solaryellow
Solaryellow Aug. 25 at 10:36 AM
$NRXP what's this D boral guy smoking? $31 to $34? I was happy with $3.40
2 · Reply
the_franz
the_franz Aug. 25 at 8:31 AM
$NRXP Funny... I just checked sunbiz.org to find the latest companies our CEO may have founded. Looks like our CEO now operates a kosher French restaurant in Miami. So he actually can close deals! 🥳 Link to FB comment (no clue if working): https://www.facebook.com/groups/gkrfoodies/posts/2882818711904087/?comment_id=2882960821889876&reply_comment_id=2932496230269668
2 · Reply
DavidBG
DavidBG Aug. 23 at 7:08 PM
$NRXP Some more thoughts: Among other things, this week's call reflected continued preparation for commercialization. Management has reached the conclusion that growing beyond the initial $100 million in annualized revenues via M&A would be difficult due to the low quality of most ketamine clinics and thus anticipates a focus on new clinics after that point. Matt Duffy has a plan for independently commercializing NRX-100 that contemplates a lean sales team in keeping with the number of establishments that would be buyers (which may and may not mean that NRXP is leaning toward going it alone). "During Q2 2025 and in subsequent events, management has focused on preparing the New Drug Application of NRX-101, submitting more than 80,000 pages of manufacturing, non-clinical, and clinical material in July 2025" (https://ir.nrxpharma.com/node/10401/html). That's clearly one of the things that have been keeping management busy.
2 · Reply
DavidBG
DavidBG Aug. 23 at 7:05 PM
$NRXP Some thoughts: "Under the terms of the Fast Track program, NRx will be posting an expanded access policy for NRX-100 in the next two weeks [...]" (https://ir.nrxpharma.com/news-releases/news-release-details/nrx-pharmaceuticals-inc-nasdaqnrxp-granted-fda-fast-track). That news is due this coming week. "A New Drug Application ('NDA') for NRX-100 [...] is expected to be completed in September 2025" (https://ir.nrxpharma.com/node/10401/html). In the past, NRXP said that completion of the NDA was waiting for receipt of a CNPV. Those two statements apparently should be read together.
1 · Reply
FounderV
FounderV Aug. 23 at 3:24 AM
$NRXP See you all next week! Bless you!
0 · Reply